Health Care • Biotechnology: Pharmaceutical Preparations
$44.99 ▼ -0.73
(-1.60%)
MKT CAP: $4.03B • VOL: 2.64M
52W L $22 52W H $94
LQDA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $158.3M | $14.0M | $17.5M |
| YoY Revenue Growth % | +1031.2% | -20.0% | — |
| Gross Profit | $69.7M | $8.1M | $7.7M |
| Gross Margin % | 44.0% | 58.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$51.4M | -$121.3M | -$73.4M |
| Operating Margin % | -32.5% | -866.6% | -419.6% |
| Net Income (GAAP) | -$68.9M | -$130.4M | -$78.5M |
| EBITDA (Normalized) | -$47.9M | -$117.3M | -$72.8M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$35.7M | -$93.4M | -$41.6M |
| Capital Expenditures (CapEx) | $4.3M | $4.9M | $787.0K |
| Free Cash Flow (FCF) | -$40.0M | -$98.4M | -$42.4M |
| FCF Margin % | -25.3% | -702.9% | -242.2% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -4.3% |
| Cash & Short-Term Equivalents | $190.7M | $176.5M | $243.6M |
| Total Debt (Short + Long Term) | $127.4M | $67.9M | $518.3M |
| Total Stockholders' Equity | $44.7M | $79.4M | $1.06B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LQDA.